# Hepcludex® (bulevirtide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bulevirtide

> Hepcludex® (bulevirtide), sponsored by GILEAD SCIENCES, INC. (GILD), received a complete response letter from the FDA; the decision is dated Oct 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Hepcludex® (bulevirtide) |
| Codes |  |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications | with hepatitis delta virus infection |
| Modality | peptide |
| FDA designations | none disclosed |

## Timeline

### Oct 2022: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month. Indication: with hepatitis delta virus infection.
- First seen 2024-11-12, last confirmed 2025-05-07.
- SEC Form 10-Q (accession 0000882095-25-000012): "For example, in October 2022, we announced that FDA issued a complete response letter for our Biologics License Application for bulevirtide for the treatment of adults with hepatitis delta virus infection." https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/gild-20250331.htm
- SEC Form 10-K (accession 0000882095-25-000006): "For example, in October 2022, we announced that FDA issued a complete response letter for our Biologics License Application for bulevirtide for the treatment of adults with hepatitis delta virus infection." https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm
- SEC Form 10-Q (accession 0000882095-24-000028): "For example, in October 2022, we announced that FDA issued a complete response letter for our Biologics License Application for bulevirtide for the treatment of adults with hepatitis delta virus infection." https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/gild-20240930.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-01-12, last confirmed 2026-11-04.
- SEC Form 10-K (accession 0001628280-26-010749): "Topline results from ECLIPSE 1 are expected in the fourth quarter of 2026, and topline results from ECLIPSE 2 and ECLIPSE 3 are expected in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-070148): "•Topline data from the pivotal ECLIPSE 1 trial are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1706431/000162828026070148/a20261104-q3ex991earningsr.htm
- SEC Form 10-Q (accession 0001628280-26-070273): "•Topline data from the pivotal ECLIPSE 1 trial are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1706431/000162828026070273/vir-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-070148): "- Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/1706431/000162828026070148/a20261104-q3ex991earningsr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-053351): "- Topline data from Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/a20260805-q2ex991earningsr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-053351): "◦Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1706431/000162828026053351/a20260805-q2ex991earningsr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-031273): "•Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1706431/000162828026031273/a20260506-q1ex991earningsr.htm
- SEC Form 10-Q (accession 0001628280-26-053549): "◦Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1706431/000162828026053549/vir-20260630.htm
- SEC Form 10-Q (accession 0001628280-26-031471): "•Topline data from the Phase 3 ECLIPSE 1 trial are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1706431/000162828026031471/vir-20260331.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-010740): "•Topline data from the ECLIPSE 1 trial are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1706431/000162828026010740/a20260223-q4ex992earningsr.htm
- Press release filed with the SEC (EX-99) (accession 0001628280-26-001768): "Topline data from the ECLIPSE 1 trial is expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1706431/000162828026001768/a2026-01x12_8xkxjpmpressre.htm
- SEC Form 10-K (accession 0001628280-26-010749): "Topline data from the ECLIPSE 1 trial are expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1706431/000162828026010749/vir-20251231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bulevirtide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hepcludex® (bulevirtide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bulevirtide

```bibtex
@misc{secapidev_pdufa_bulevirtide_20261116,
  title        = {Hepcludex® (bulevirtide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bulevirtide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bulevirtide_20261116","title":"Hepcludex® (bulevirtide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bulevirtide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
